Longevity & AgingAlzheimer's pill MNA-001 clears early safety trial and shifts aging brain markers
Muna Therapeutics reported positive Phase 1 results for MNA-001, an oral pill that modulates TREM2, a receptor on the brain's immune cells (microglia) tied to Alzheimer's disease. The randomized, double-blind, placebo-controlled study tested single and repeated rising doses in younger volunteers, plus an elderly group. The company reports no serious adverse events, no dropouts due to side effects, and mostly mild complaints. The drug reached the cerebrospinal fluid, the fluid surrounding the brain and spinal cord, in substantial amounts and behaved similarly in younger and older participants. Levels of soluble TREM2, a marker showing the drug is hitting its target, fell in a dose-dependent way before leveling off. In an exploratory analysis, older volunteers' spinal fluid markers of microglial activity, innate immune activation and neuronal stress moved toward levels seen in younger people. A placebo-controlled Phase 2 study with cognitive testing is planned for early 2027. These are early, company-reported results: safety and target engagement, not proof the drug helps memory or slows Alzheimer's.
